Impax Laboratories Inc. (IPXL) Tops Q2 EPS by 24c

Impax Laboratories Inc. (NASDAQ: IPXL) reported Q2 EPS of $0.60, $0.24 better than the analyst estimate of $0.36. Revenue for the quarter came in at $188.1 million versus the consensus estimate of $155.97 million.

For earnings history and earnings-related data on Impax Laboratories Inc. (IPXL) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Innovaro (INV) Misses Q2 EPS by 9c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance